Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; microSelectron, a digital pulsed dose rate platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Elekta Neuromag TRIUX, a magnetoencephalography system; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone46-8-587-254-00
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.37 billion
Profitability
Miscellaneous
Employees3,716
Next Earnings Date6/7/2019 (Estimated)
OptionableNot Optionable
ELEKTA AB/ADR (OTCMKTS:EKTAY) Frequently Asked Questions
What is ELEKTA AB/ADR's stock symbol?
ELEKTA AB/ADR trades on the OTCMKTS under the ticker symbol "EKTAY."
How often does ELEKTA AB/ADR pay dividends? What is the dividend yield for ELEKTA AB/ADR?
ELEKTA AB/ADR declared a Semi-Annual dividend on Wednesday, January 30th. Investors of record on Monday, March 4th will be paid a dividend of $0.052 per share on Friday, March 22nd. The ex-dividend date is Friday, March 1st. View ELEKTA AB/ADR's Dividend History.
How were ELEKTA AB/ADR's earnings last quarter?
ELEKTA AB/ADR (OTCMKTS:EKTAY) posted its quarterly earnings results on Friday, February, 22nd. The company reported $0.06 EPS for the quarter. The firm had revenue of $367.04 million for the quarter. ELEKTA AB/ADR had a return on equity of 16.86% and a net margin of 9.35%. View ELEKTA AB/ADR's Earnings History.
When is ELEKTA AB/ADR's next earnings date?
What is the consensus analysts' recommendation for ELEKTA AB/ADR?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ELEKTA AB/ADR in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ELEKTA AB/ADR.
Has ELEKTA AB/ADR been receiving favorable news coverage?
News stories about EKTAY stock have trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ELEKTA AB/ADR earned a coverage optimism score of -1.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the immediate future.
Who are some of ELEKTA AB/ADR's key competitors?
Some companies that are related to ELEKTA AB/ADR include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Guardant Health (GH), Genomic Health (GHDX), InVitae (NVTA), Natera (NTRA), CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Fulgent Genetics (FLGT), Miragen Therapeutics (MGEN), PotNetwork (POTN) and Psychemedics (PMD).
What other stocks do shareholders of ELEKTA AB/ADR own?
Who are ELEKTA AB/ADR's key executives?
ELEKTA AB/ADR's management team includes the folowing people:
- Mr. Laurent Leksell, Founder & Chairman (Age 67)
- Dr. Richard Hausmann, Pres & CEO (Age 59)
- Mr. Gustaf Salford, CFO & Exec. VP (Age 42)
- Mr. Steven Wort, COO & Group VP of Manufacturing & Logistics (Age 56)
- Mr. John Lapré, Chief Technology Officer (Age 55)
How do I buy shares of ELEKTA AB/ADR?
Shares of EKTAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ELEKTA AB/ADR's stock price today?
One share of EKTAY stock can currently be purchased for approximately $10.95.
How big of a company is ELEKTA AB/ADR?
ELEKTA AB/ADR has a market capitalization of $4.04 billion and generates $1.37 billion in revenue each year. The company earns $132.53 million in net income (profit) each year or $0.35 on an earnings per share basis. ELEKTA AB/ADR employs 3,716 workers across the globe.
What is ELEKTA AB/ADR's official website?
How can I contact ELEKTA AB/ADR?
ELEKTA AB/ADR's mailing address is P.O. Box 7593, Stockholm V7, SE-103 93. The company can be reached via phone at 46-8-587-254-00 or via email at [email protected]
MarketBeat Community Rating for ELEKTA AB/ADR (OTCMKTS EKTAY)
MarketBeat's community ratings are surveys of what our community members think about ELEKTA AB/ADR and other stocks. Vote "Outperform" if you believe EKTAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EKTAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
